利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.027 秒)

    Immunising Against Meningococcal Serogroup Y Using Proteins
    1.
    发明申请
    Immunising Against Meningococcal Serogroup Y Using Proteins 审中-公开
    使用蛋白免疫脑膜炎球菌血清群Y

    公开(公告)号：US20100143418A1

    公开(公告)日：2010-06-10

    申请号：US11587189

    申请日：2005-04-22

    申请人： Mario Contorni ,  Marzia Giuliani ,  Mariagrazia Pizza

    发明人： Mario Contorni ,  Marzia Giuliani ,  Mariagrazia Pizza

    IPC分类号： A61K39/095 ,  A61P31/04

    CPC分类号： A61K39/095

    摘要： The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W135 and Y.

    摘要翻译： 本发明使用多肽抗原和/或OMV免疫血清群A，C，W135和Y（特别是针对血清群Y）。 血清群B多肽可以实现这种保护，从而允许单一的基于多肽的疫苗用于保护所有血清群A，B，C，W135和Y.

    Vaccines comprising aluminium adjuvants and histidine
    4.
    发明授权
    Vaccines comprising aluminium adjuvants and histidine 有权
    包含铝佐剂和组氨酸的疫苗

    公开(公告)号：US07348006B2

    公开(公告)日：2008-03-25

    申请号：US10484702

    申请日：2002-07-26

    申请人： Mario Contorni ,  Massimo Maffei

    发明人： Mario Contorni ,  Massimo Maffei

    IPC分类号： A61K39/00 ,  C07H21/02

    CPC分类号： A61K38/00 ,  A61K39/095 ,  A61K39/39 ,  A61K2039/55505 ,  Y02A50/466

    摘要： To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can be reduce antigen hydrolysis. Histidine is preferably presen during adsorption to the aluminium salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.

    摘要翻译： 为了提高包含铝盐的疫苗的稳定性，本发明使用氨基酸组氨酸。 这可以改善pH稳定性和辅助吸附，并可以减少抗原水解。 组氨酸优选在吸附到铝盐期间发生。 疫苗中的抗原可以是蛋白质或糖，并且优选来自脑膜炎奈瑟氏球菌。

    Combination vaccines with low dose of Hib conjugate
    5.
    发明授权
    Combination vaccines with low dose of Hib conjugate 有权
    联合疫苗与低剂量的Hib缀合物

    公开(公告)号：US09259460B2

    公开(公告)日：2016-02-16

    申请号：US13250094

    申请日：2011-09-30

    申请人： Mario Contorni

    发明人： Mario Contorni

    IPC分类号： A61K39/095 ,  A61K39/08 ,  A61K39/05 ,  A61K39/02 ,  A61K39/102

    CPC分类号： A61K39/08 ,  A61K39/05 ,  A61K39/099 ,  A61K39/102 ,  Y02A50/466

    摘要： Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is

    摘要翻译： 本文提供了包含用于保护受试者免受至少白喉，破伤风，百日咳和Hib的抗原的组合疫苗，其中：（a）用于保护Hib的抗原是Hib荚膜糖的缀合物; （b）疫苗中Hib缀合物的浓度<15μg/ ml; 和（c）Hib偶联物从未被冻干。

    IMMUNOGENIC COMPOSITIONS
    6.
    发明申请
    IMMUNOGENIC COMPOSITIONS 审中-公开
    免疫组化

    公开(公告)号：US20130273091A1

    公开(公告)日：2013-10-17

    申请号：US13824041

    申请日：2011-09-16

    申请人： Francesco Berti ,  Mario Contorni ,  Paolo Costantino ,  Oretta Finco ,  Guido Grandi ,  Domenico Maione ,  John Telford

    发明人： Francesco Berti ,  Mario Contorni ,  Paolo Costantino ,  Oretta Finco ,  Guido Grandi ,  Domenico Maione ,  John Telford

    IPC分类号： A61K39/385

    CPC分类号： A61K39/385 ,  A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/627

    摘要： The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof.

    摘要翻译： 本发明提供免疫原性组合物，其包含：a）缀合物，其是与载体蛋白缀合的GBS血清型1a的荚膜糖; b）缀合物，其是与载体蛋白质缀合的GBS血清型1b的荚膜糖; 和c）缀合物，其是与载体蛋白质缀合的GBS血清型III的荚膜糖。 本发明还提供了一种用于免疫患者免受GBS感染的方法，包括向患者施用作为与白喉类毒素或其衍生物缀合的GBS的荚膜糖的缀合物的步骤，其中所述患者已经用 白喉类毒素或其衍生物。

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    7.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 审中-公开

    公开(公告)号：US20120070458A1

    公开(公告)日：2012-03-22

    申请号：US13260534

    申请日：2010-03-24

    申请人： Mario Contorni ,  Lorenzo Tarli

    发明人： Mario Contorni ,  Lorenzo Tarli

    IPC分类号： A61K39/095 ,  A61P31/04 ,  A61K39/385

    CPC分类号： A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    摘要： Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT
    8.
    发明申请
    INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT 审中-公开
    具有减少乳剂含量的流感疫苗

    公开(公告)号：US20090304742A1

    公开(公告)日：2009-12-10

    申请号：US12092142

    申请日：2006-11-06

    申请人： Mario Contorni

    发明人： Mario Contorni

    IPC分类号： A61K39/145

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/55566 ,  A61K2039/6093 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16134 ,  C12N2760/16234

    摘要： Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form.

    摘要翻译： 具有水包油乳液佐剂的流感疫苗是已知的。 可以减少流感疫苗所需的乳剂佐剂的量，从而允许从给定量的乳液制备更多的疫苗，和/或最小化必须在给定数量的疫苗剂量下产生的乳液的量。 这些疫苗可以方便地通过混合（i）水包油乳液和（ii）流感病毒抗原的水性制剂来制备。 在一个方面，使用基本相同体积的组分（i）和（ii）; 在另一方面，使用过量的组分（ii）。 当使用基本上相等的体积时，组分（ii）的血凝素浓度大于60mug流感病毒株/ ml。 组分（i）和（ii）可以以试剂盒形式提供。

    Liquid vaccines for multiple meningococcal serogroups
    9.
    发明授权
    Liquid vaccines for multiple meningococcal serogroups 有权
    液体疫苗用于多种脑膜炎球菌血清群

    公开(公告)号：US08765135B2

    公开(公告)日：2014-07-01

    申请号：US10574424

    申请日：2004-10-04

    申请人： Mario Contorni

    发明人： Mario Contorni

    IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/095 ,  A61K39/116

    CPC分类号： A61K47/4833 ,  A61K9/19 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

    摘要： Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.

    摘要翻译： 来自脑膜炎球菌血清群C，W135和Y的共轭荚膜糖在单剂量组合时在人体中是安全的和免疫原性的。 当加入来自血清群A的共轭荚膜糖时，保留这种效果。 这些缀合的抗原可以单一水剂量稳定地组合，而不需要冻干。 通过使用少量定义的多肽抗原可以实现对血清群B感染的广泛保护。 这些多肽抗原可以与糖抗原组合，而不会损害五种血清群中的任何一种的保护功效。 即使添加Hib缀合物也能保留效力。 通过加入源自血清群B菌株的蛋白质抗原来增强血清群W135缀合物的功效。 向脑膜炎球菌共轭物中添加Hib缀合物增强了针对脑膜炎球菌血清群W135的总体活性。